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Purpose: The Stickler syndromes are the most common causes of inherited and childhood retinal detach-
ment; however, no consensus exists regarding the effectiveness of prophylactic intervention. We evaluate the
long-term safety and efﬁcacy of the Cambridge prophylactic cryotherapy protocol, a standardized retinal pro-
phylactic treatment developed to prevent retinal detachment arising from giant retinal tears in type 1 Stickler
syndrome.
Design: Retrospective comparative case series.
Participants: Four hundred eighty seven patients with type 1 Stickler syndrome.
Methods: Time to retinal detachment was compared between patients who received bilateral prophylaxis
and untreated controls, with and without individual patient matching. Patients receiving unilateral prophylaxis
(after fellow eye retinal detachment) were similarly compared with an appropriate control subgroup. Individual
patient matching ensured equal age and follow-up between groups and that an appropriate control (who had not
suffered a retinal detachment before the age at which their individually matched treatment patient underwent
prophylactic treatment) was selected. Matching was blinded to outcome events. Individual patient matching
protocols purposely weighted bias against the effectiveness of treatment. All treatment side effects are reported.
Main Outcome Measures: Time to retinal detachment and side effects occurring after prophylactic
treatment.
Results: The bilateral control group (n ¼ 194) had a 7.4-fold increased risk of retinal detachment compared to
the bilateral prophylaxis group (n ¼ 229) (hazard ratio [HR], 7.40; 95% conﬁdence interval [CI], 4.53e12.08;
P<0.001); the matched bilateral control group (n ¼ 165) had a 5.0-fold increased risk compared to the matched
bilateral prophylaxis group (n¼ 165) (HR, 4.97; 95% CI, 2.82e8.78; P<0.001). The unilateral control group (n¼ 104)
had a 10.3-fold increased risk of retinal detachment compared to the unilateral prophylaxis group (n ¼ 64) (HR,
10.29; 95% CI, 4.96e21.36; P<0.001); the matched unilateral control group (n ¼ 39) had a 8.4-fold increased risk
compared to the matched unilateral prophylaxis group (n ¼ 39) (HR, 8.36; 95% CI, 3.24e21.57; P<0.001). No
signiﬁcant long-term side effects occurred.
Conclusions: In the largest global cohort of type 1 Stickler syndrome patients published, all analyses indi-
cate that the Cambridge prophylactic cryotherapy protocol is safe and markedly reduces the risk of retinal
detachment. Ophthalmology 2014;121:1588-1597 ª 2014 by the American Academy of Ophthalmology.
Supplemental video is available at www.aaojournal.org.The Stickler syndromes are among the most frequently
inherited connective tissue disorders, with an estimated
incidence of 1:7500 live births; they are the most common
cause of inherited and childhood retinal detachment.1,2
Originally considered a single gene disorder, at least 6 sub-
groups have been characterized according to genetic abnor-
malities of type II, IX, or XI collagen.3e10 These structural
proteins are principally and collectively expressed in the eye
and in articular and hyaline cartilage. Affected patients pre-
sent with premature arthropathy and classic orofacial, audi-
tory, and ocular features.1,11e13 More than 80% of affected
patients have type 1 Stickler syndrome.14,151588  2014 by the American Academy of Ophthalmology
Published by Elsevier Inc. Open access under CC BY-NC-ND license.To date, no prospective, randomized trial investigating the
prevention of nonsyndromic retinal detachment has been con-
ducted.16 Evidence informing current clinical practice does not
support prophylactically treating asymptomatic breaks or lattice
degeneration.17 Prophylactic treatment may prevent tear
formation within treated areas but does not preclude or predict
tears occurring elsewhere in the retina.18
Type 1 Stickler syndrome, however, lends itself as a prime
model for retinal prophylaxis because it is genetically deﬁned
and identiﬁable15,19 and recognized as the subgroup with the
highest risk of retinal detachment.2 Patients typically develop
retinal detachments from giant retinal tear formation at theISSN 0161-6420/14/$ - see front matter
http://dx.doi.org/10.1016/j.ophtha.2014.02.022
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opportunity for a speciﬁc prophylactic strategy to prevent
such tears from progressing to retinal detachment.
The Cambridge prophylactic cryotherapy protocol was
developed with the speciﬁc rationale of preventing retinal
detachment arising from giant retinal tears. For over 37
years, prophylaxis has been offered to all type 1 Stickler
syndrome patients and deployed in a standardized, uniform
manner.20 We report results on the largest global cohort of
type 1 Stickler syndrome patients with regard to the
efﬁcacy and safety of this standardized protocol in reducing
the risk of retinal detachment and blindness.
Methods
Patients and Study Design
Patients with type 1 Stickler syndrome (Online Mendelian Inheri-
tance in Man no. 108300) were retrospectively identiﬁed from the
Vitreoretinal Research Unit database, clinical records, and research
pedigree ﬁles, the diagnosis being made according to published
clinical criteria.1 All patients who received any form of
nonstandardized prophylaxis (including any previous focal laser
or cryotherapy to identiﬁed retinal breaks or areas of lattice
degeneration, previous 360 prophylactic laser retinopexy, previous
prophylactic scleral buckling, or previous 360 prophylactic
cryotherapy undertaken in other eye units, but completed posterior
to the oral retina [equatorially]) were excluded. Only patients with
both eyes available for study were included.
Mutation analysis was conﬁrmed in the majority of cases and in
every case where vitreous phenotyping was not possible due to
previous bilateral vitrectomy.
Patients were divided into 4 groups for analysis. (1) The
bilateral prophylaxis group comprised patients who had suffered
no previous retinal detachment and had undergone the Cambridge
prophylactic cryotherapy protocol to both eyes. (2) The bilateral
control group comprised patients who had not undergone the
prophylactic protocol (patients may have suffered unilateral,
bilateral, or no previous retinal detachment). (3) The unilateral
prophylaxis group comprised patients who had undergone the
prophylactic protocol after retinal detachment in their fellow eye.
(4) The unilateral control group comprised patients who had not
undergone the prophylactic protocol but suffered previous unilat-
eral or bilateral retinal detachment (control subgroup).
Primary Outcome Measures
We measured (1) time to retinal detachment (this also included any
case requiring further retinopexy after prophylactic cryotherapy but
without formal retinal detachment repair) and (2) side effects
resulting from prophylactic treatment.
Outcomes between groups receiving the Cambridge prophy-
lactic cryotherapy protocol and their respective controls were
retrospectively compared. To account for differences in age and
follow-up duration, individual patient matching was undertaken
between the bilateral prophylaxis and bilateral control groups, and
the unilateral prophylaxis and unilateral control groups (see
matching protocols below). To facilitate equal age at last review
between matched pairs, a control group follow-up “cropping” step
was implemented; any retinal detachment that occurred during this
“cropped” period was discarded because it did not occur during the
matched follow-up time. Matching created comparison groups
exactly equal in number, age, and follow-up duration, and in which
patients receiving prophylaxis did so before any potential retinal
detachment event in their individually matched control.Matching Protocol 1: Bilateral Prophylaxis versus
Bilateral Control Group1. All bilateral prophylaxis group patients with both eyes
available for analysis were included for matching.
2. Observers were blinded to prophylactic cryotherapy fail-
ure status.
3. All bilateral prophylaxis group patients were arranged in
descending order of length of follow-up after prophylactic
cryotherapy. Those patients with less than 1 year of
follow-up after prophylactic cryotherapy were excluded
from further analysis.
4. The bilateral prophylaxis group patient with the longest
follow-up after prophylactic cryotherapy was selected for
matching. The age at which this patient underwent pro-
phylactic cryotherapy and their age at last review were
noted for subsequent control matching.
5. All bilateral control group patients with both eyes avail-
able for analysis were included for matching.
6. From the bilateral control group, all patients who had their
ﬁrst retinal detachment at an age equal to or less than the
age at which the selected bilateral prophylaxis group pa-
tient had their prophylactic cryotherapy were excluded
from the current round of matching (but returned to the
bilateral control group for subsequent rounds of matching).
7. Observers were blinded to the retinal detachment status in
this selected subgroup of bilateral control group patients
available for the current round of matching.
8. From this subgroup, the patient with an equal or next
closest (but older) age at last review was selected to be
matched to the selected bilateral prophylaxis group pa-
tient (if no control group patient had an equal or older age
at last review, the selected prophylaxis group patient was
considered unmatched and excluded from further match-
ing analysis; analysis would then restart from step 4).
9. Once matched, these patients were removed from their
respective bilateral prophylaxis and bilateral control
groups and made unavailable for further matching.
10. Steps 4 through 9 were repeated, using the bilateral pro-
phylaxis group patient with the next longest post-
prophylactic cryotherapy follow-up as the next selected
case for matching.
11. Matching continued until all bilateral prophylaxis group
patients had been matched to an appropriate bilateral
control or were excluded from matching.
12. Thematchedbilateral prophylaxis andbilateral control group
patients were unmasked with regard to prophylactic cryo-
therapy failure and retinal detachment status, respectively.
13. Individual patient ages at last review in the matched bilateral
control group (purposely selected to be equal in age or older)
were comparedwith the individual patient ages at last review
in the corresponding matched bilateral prophylaxis group
and “cropped” accordingly to equal the age at last review of
their match. Any retinal detachment events that occurred in
the matched bilateral control group patients during this
“cropped” period were excluded from further analysis.
14. Prevalence of retinal detachment was then compared be-
tween the matched bilateral prophylaxis and “cropped”
matched bilateral control groups.Matching Protocol 2: Unilateral Prophylaxis versus
Unilateral Control Group1. All unilateral prophylaxis group patients with both eyes
available for analysis were included for matching.1589
Ophthalmology Volume 121, Number 8, August 2014
1592. Observers were blinded to prophylactic cryotherapy fail-
ure status.
3. All unilateral prophylaxis group patients were arranged
in descending order of length of follow-up after
prophylactic cryotherapy. Those patients with less than
1 year of follow-up after prophylactic cryotherapy were
excluded from further analysis.
4. The unilateral prophylaxis group patient with the longest
follow-up after prophylactic cryotherapy was selected for
matching. The age at which this patient suffered their ﬁrst
retinal detachment (untreated eye), the age at which they
underwent prophylactic cryotherapy (treated eye), and
their age at last review were noted for subsequent control
matching.
5. All unilateral control group patients with both eyes
available for analysis were included for matching.
6. Observers were blinded to retinal detachment status in the
second eye.
7. The unilateral control group patient with an age of ﬁrst
retinal detachment closest to that of the selected unilateral
prophylaxis group patient’s age of ﬁrst retinal detachment
was selected for further matching (if there was a differ-
ence of greater than 3 years, the selected unilateral pro-
phylaxis group patient was considered unmatched and
excluded from further matching analysis; analysis would
then restart from step 4).
8. If the selected unilateral control group patient’s age at last
review was equal to or older than the selected unilateral
prophylaxis group patient’s age at last review, they were
considered for the ﬁnal matching step (if the age at ﬁnal
review was less than the selected unilateral prophylaxis
group patient’s age at last review, the matching process
returned to step 7, selecting the unilateral control group
patient with the next closest age of ﬁrst retinal detachment).
9. The ﬁnal matching step involved unmasking the selected
unilateral control group patient’s retinal detachment status
in their second eye. If the selected unilateral control group
patient did not have a second retinal detachment event or
the age at which they had their second retinal detachment
was older than the age at which the selected unilateral
prophylaxis group patient had their prophylactic cryo-
therapy, they were considered an appropriate match (if the
selected unilateral control group patient’s age at second
retinal detachment was the same or younger than the age
at which the selected unilateral prophylaxis group patient
had their cryotherapy, the match was considered inap-
propriate and the matching process returned to step 7,
selecting the unilateral control group patient with the next
closest age of ﬁrst retinal detachment).
10. Once matched, these patients were removed from their
respective unilateral prophylaxis and unilateral control
groups and made unavailable for further matching.
11. Steps 4 through 10 were repeated using the unilateral
prophylaxis group patient with the next longest follow-up
after prophylactic cryotherapy as the next selected case
for matching.
12. Matching continued until all unilateral prophylaxis group
patients had been matched to an appropriate control or
were excluded from matching.
13. The matched unilateral prophylaxis group patients were
unmasked with regard to prophylactic cryotherapy failure.
14. Individual patient ages at last review in the matched
unilateral control group (purposely selected to be equal in
age or older) were compared with the individual patient
ages at last review in the corresponding matched0unilateral prophylaxis group and “cropped” accordingly
to equal the age at last review of their match. Any retinal
detachment event that occurred in the matched unilateral
control group patients during this “cropped” period were
excluded from further analysis.
15. The prevalence of retinal detachment was then compared
between the matched unilateral prophylaxis and “crop-
ped” matched unilateral control groups.The Cambridge Prophylactic Cryotherapy
Protocol20
Informed, written consent was obtained from all patients electing to
undergo prophylactic treatment. Under general anesthesia, care-
fully monitored 360 transconjunctival prophylactic cryotherapy
was applied in a contiguous ribbon at the junction of the postoral
retina with the pars plana (Fig 1; procedure Video available at
www.aaojournal.org).
Side Effects
The occurrence of the following prophylaxis side effects was
assessed: change in pre- and postoperative visual acuity, lid and
conjunctival inﬂammation, accommodation insufﬁciency, discom-
fort, photophobia, macular pucker, and any perioperative surgical
complication. Anesthetic recovery records were reviewed for epi-
sodes of nausea or vomiting.
Statistical Analysis
KaplaneMeier survival curves and log-rank tests were used to
compare time-to-event outcomes between patients. For the bilateral
prophylaxis versus bilateral control group, the primary outcome
was time from birth to ﬁrst retinal detachment. However, for the
matched bilateral prophylaxis versus matched bilateral control
group, it was time from cryotherapy (or the corresponding time in
the individually matched control) to ﬁrst retinal detachment. For
the unilateral prophylaxis versus unilateral control group, the pri-
mary outcome was time from ﬁrst retinal detachment to second
retinal detachment. However, for the matched unilateral prophy-
laxis versus matched unilateral control group, it was time from
cryotherapy (or the corresponding time in the individually matched
control) to second retinal detachment. Sex-adjusted hazard ratios
for treatment effect and 95% conﬁdence intervals (CIs) were
calculated using Cox proportional hazards regression models. All
statistical tests were 2-sided and used a 5% signiﬁcance level.
Analyses were completed using SPSS software 21.0 (IBM Corp.,
Armonk, NY).
Results
Four hundred eighty-seven patients with type 1 Stickler syndrome
from 239 family pedigrees met the inclusion criteria; 229 under-
went bilateral prophylaxis, 64 underwent unilateral prophylaxis,
and 194 received no prophylactic intervention (104 of whom
qualiﬁed for the unilateral control subgroup). Of these, 426 patients
(87.5%) were tested for COL2A1 mutations; the mutation detection
rate using the Cambridge 2-stage diagnostic screening strategy19
was 96.9% at the time of study completion. Demographic details
are given in Table 1.
Bilateral Prophylaxis versus Bilateral Control Group
The prevalence of retinal detachment in the bilateral prophylaxis
group was 8.3% (19/229), of which 7.9% (18/229) were unilateral
Figure 1. Noncontact, high-resolution ultrawide-ﬁeld fundal photography, annotated to demonstrate the standardized anterior positioning of retinal cry-
opexy applied during the Cambridge prophylactic cryotherapy protocol. Individual cryotherapy applications (white dotted circles) touch shoulder to
shoulder and include the ora serrata (dotted red line).
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the bilateral control group was 53.6% (104/194), of which 10.3%
(20/194) were unilateral and 43.3% (84/194) bilateral (Fig 2). Of
the 20 retinal detachment events occurring after prophylaxis, 12
required surgical repair and 8 were managed with additional
retinopexy alone; all 188 control group retinal detachments
required formal surgical repair.
The median time to ﬁrst retinal detachment was 18.28 years
(95% CI, 14.92e21.63) in the bilateral control group; a median
time was not reached in the bilateral prophylaxis group (Fig 3A).
The hazard ratio of having a retinal detachment without
prophylaxis, based on treatment effect adjusted for sex, was 7.40
(95% CI, 4.53e12.08; P<0.001) (Table 2).Matched Bilateral Prophylaxis versus Matched
Bilateral Control Group
The individual matching protocol resulted in 165 patients with equal
age at last review and follow-up duration being paired for compar-
ison. The prevalence of retinal detachment in the matched bilateral
prophylaxis group was 9.1% (15/165), of which 8.5% (14/165) were
unilateral and 0.6% (1/165) bilateral. The prevalence of retinal
detachment in the matched bilateral control group was 37.0% (61/
165), of which 16.4% (27/165) were unilateral and 20.6% (34/165)
bilateral (Fig 2). Of the 16 retinal detachment events occurring after
prophylaxis, 12 required surgical repair and 4 were managed with
additional retinopexy alone; all 95 matched control group retinal
detachments required formal surgical repair. Before “cropping,”
the prevalence of retinal detachment in the matched bilateral
control group was 61.8% (102/165); 89 retinal detachment events
were “cropped” and omitted from analysis.The median time to retinal detachment was 16.41 years (95%
CI, 5.31e27.51) in the matched bilateral control group; a median
time was not reached in the matched bilateral prophylaxis group
(Fig 3B). The hazard ratio of having a retinal detachment without
prophylaxis, based on treatment effect adjusted for sex, was 4.97
(95% CI, 2.82e8.78; P<0.001) (Table 2).
Unilateral Prophylaxis versus Unilateral Control
Group
The prevalence of second eye retinal detachment in the unilateral
prophylaxis group was 12.5% (8/64) compared with 80.8% (84/104)
in the unilateral control group (Fig 2). Of the 8 retinal detachment
events occurring after prophylaxis, 6 required surgical repair and 2
were managed with additional retinopexy alone; all 84 second eye
retinal detachments in the control group required formal surgical
repair.
The median time to second eye retinal detachment was 4.00
years (95% CI, 2.17e5.83) in the unilateral control group
compared with 51.60 years (95% CI, 13.29e88.83) in the unilat-
eral prophylaxis group (Fig 3C). The hazard ratio of having a
second eye retinal detachment without prophylaxis, based on
treatment effect adjusted for sex, was 10.29 (95% CI,
4.96e21.36; P<0.001) (Table 2).
Matched Unilateral Prophylaxis versus Matched
Unilateral Control Group
The individual matching protocol resulted in 39 patients with equal
age at last review and follow-up duration being paired for compar-
ison. The prevalence of second eye retinal detachment in the
matched unilateral prophylaxis group was 15.4% (6/39) compared1591
Table 1. Matched and Unmatched Prophylactic and Control Group Demographics
Group
No. of
Patients
Sex Ratio
(M:F)
Mean Age (SD)
at Last Review
(yrs)
Mean Age (SD) at
First Retinal
Detachment (yrs)
Mean Age (SD)
at Second Retinal
Detachment (yrs)
Mean Age (SD)
at Prophylaxis
(yrs)
Mean (SD) Follow-up
after Prophylaxis
(yrs)
Bilateral prophylaxis group 229 104:125 20.8 (16.9) d d 14.5 (15.9) 6.3 (6.4)
No RD 210 92:118 19.6 (16.6) d d 13.7 (15.3) 5.9 (6.0)
Unilateral RD 18 11:7 34.6 (19.6) 29.3 (19.4) d 24.1 (20.4) 10.6 (9.0)
Bilateral RD 1 1:0 10.9 4.19 4.19 4.0 6.8
Bilateral control group 194 95:99 31.3 (21.6) d d d d
No RD 90 38:52 18.6 (18.6) d d d d
Unilateral RD 20 9:11 37.0 (24.6) 24.8 (20.4) d d d
Bilateral RD 84 48:36 43.4 (15.7) 15.2 (10.4) 22.0 (13.8) d d
Matched bilateral
prophylaxis group 165 78:87 19.8 (15.0) d d 11.6 (12.9) 7.7 (6.2)
No RD 150 68:82 18.8 (14.3) d d 10.9 (12.3) 7.8 (6.0)
Unilateral RD 14 9:5 31.9 (17.5) 25.5 (16.8) d 19.1 (17.0) 12.8 (9.0)
Bilateral RD 1 1:0 10.9 4.19 4.19 4.0 6.8
Matched bilateral control
group 165 83:82 19.8 (15.0) d d d d
No RD 104 48:56 19.5 (15.8) d d d d
Unilateral RD 34 17:10 18.4 (13.2) 15.2 (13.1) d d d
Bilateral RD 27 18:16 22.0 (14.1) 14.8 (12.1) 16.9 (12.0) d d
Unilateral prophylaxis
group 64 37:27 33.2 (18.0) 16.9 (13.5) d 22.9 (15.7) 10.1 (10.4)
Unilateral RD 56 31:25 32.2 (18.3) 17.4 (13.9) d 23.3 (15.6) 9.0 (9.7)
Bilateral RD 8 6:2 40.1 (14.2) 13.1 (10.2) 27.8 (15.8) 20.0 (17.6) 19.2 (11.8)
Unilateral control group 104 57:47 42.2 (17.8) 17.0 (13.4) d d d
Unilateral RD 20 9:11 37.0 (24.6) 24.8 (20.4) d d d
Bilateral RD 84 48:36 43.4 (15.7) 15.2 (10.4) 22.0 (13.8) d d
Matched unilateral
prophylaxis group 39 23:16 31.4 (16.3) 14.2 (11.8) d 17.8 (13.3) 13.7 (11.1)
Unilateral RD 33 19:14 30.7 (17.0) 14.9 (12.6) d 19.0 (14.0) 11.7 (10.2)
Bilateral RD 6 4:2 35.5 (12.4) 10.6 (5.7) 21.0 (9.6) 11.1 (5.9) 24.6 (9.8)
Matched unilateral control
group 39 27:12 31.4 (16.3) 14.4 (11.6) d d d
Unilateral RD 12 9:3 28.8 (16.7) 13.8 (13.2) d d d
Bilateral RD 27 18:9 32.6 (16.31) 14.7 (11.1) 23.4 (14.1) d d
M:F ¼ male:female; RD ¼ retinal detachment; SD ¼ standard deviation.
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Of the 6 retinal detachment events occurring after prophylaxis,
5 required surgical repair and 1 was managed with additional
retinopexy alone; all 27 matched control group second eye retinal
detachments required formal surgical repair. Before “cropping,”
the incidence of second eye retinal detachment in the matched
unilateral control group was 87.2% (34/39); 7 second eye retinal
detachments were “cropped” and omitted from analysis.
The median time to second eye retinal detachment was 5.93
years (95% CI, 0.00e13.66) in the matched unilateral control group;
a median time was not reached in the matched unilateral prophylaxis
group (Fig 3D). The hazard ratio of having a second eye retinal
detachment without prophylaxis, based on treatment effect
adjusted for sex, was 8.36 (95% CI, 3.24e21.57; P<0.001)
(Table 2).
Prophylaxis Failure
Failure of retinal cryotherapy prophylaxis occurred in 9.0%
(27/299) of patients receiving treatment. The average age at the
time of the cryotherapy procedure in the failed cases was 21.5
years (range, 2.4e59.6 years; standard deviation, 19.2 years) and
the average time from treatment to prophylaxis failure was 5.6
years (range, 0.1e22.4 years; standard deviation, 7.2 years).1592Eighteen eyes required formal surgical retinal detachment
repair. Six of these cases were due to retinal breaks identiﬁed
posteriorly and 5 cases were attributed to treated anterior breaks
being lifted off or extending through the cryotherapy treatment
barrier. There was a single case treated for a break that developed
at the junction of the posterior edge of the cryotherapy treatment
and untreated retina. No data were available for 6 cases requiring
surgical retinal detachment repair, 2 of which presented with
associated proliferative vitreoretinopathy owing to delayed pre-
sentation after retinal detachment.
Of the 10 cases of prophylaxis classed as “failure” but managed
with additional retinopexy alone, 7 cases were for retinal breaks
occurring posteriorly (3 of which had associated subretinal ﬂuid), 2
cases were for localized retinal detachments that were being held
by the cryotherapy treatment (but a further retinopexy barrier was
applied for additional security), and 1 case was for a suspected
break at the junction of the posterior edge of the cryotherapy-
treated and untreated retina.
All failure cases were unilateral except one bilateral case, which
developed in a 4-year-old child with a coexisting diagnosis of
Down syndrome; the operation record documented concerns
regarding the appearance of the peripheral retina at the time of
cryotherapy. Bilateral prophylactic cryotherapy failure was diag-
nosed 51 days after treatment; the right retinal detachment had
Figure 2. Prevalence of unilateral and bilateral retinal detachments (RDs) in matched and unmatched prophylactic and control groups.
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detachment was secondary to an inferior horseshoe tear located
posteriorly to the treatment barrier.
Side Effects
The Cambridge prophylactic cryotherapy protocol caused no re-
ported signiﬁcant long-term side effects in any of the 293 patients
who underwent treatment. In particular, no cases of choroidal
hemorrhage, macular pucker, or unexplained visual loss occurred.
The mean logarithm of the minimum angle of resolution visual
acuity before and after prophylaxis, recorded in 414 eyes (182
bilateral prophylactic and 50 unilateral prophylactic group pa-
tients), was 0.29 (range, -0.18e1.80; standard deviation, 0.29) and
0.25 (range, -0.18e1.30; standard deviation, 0.24), respectively. At
review, visual acuity was the same or better than preoperative
acuity readings in all patients, except for a single 38.4-year-old
patient with a previously diagnosed Foster Fuch’s spot and pro-
gressive macular atrophy, who did not regain unilateral preopera-
tive vision. Table 3 summarizes all reported side effects.Discussion
The risk of retinal detachment in patients with type 1 Stickler
syndrome is very high.20e23 The oldest patient in the current
series to suffer their ﬁrst retinal detachment was 78.5 years.
The median survival time to ﬁrst retinal detachment in the
bilateral control group was 18.3 years, and the median sur-
vival time from ﬁrst to second retinal detachment in the
unilateral control group was 4.0 years. The most disturbingcases, however, are the late presentations of preverbal chil-
dren with inoperable bilateral retinal detachments. Severe
visual loss, compounded by the hearing, speech, and mobility
problems associated with this disorder, results in a signiﬁcant,
life-long impact on the future of these young people.
Recent development and provision of 2-stage diagnostic
screening19 means that type 1 Stickler syndrome can now be
accurately identiﬁed and conﬁrmed in over 90% of cases.15
Further reﬁnement with specialized minigene and multiplex
ligation-dependent probe ampliﬁcation analysis has resulted
in a mutation detection rate of 96.9% at the time of
completion of this study (Department of Health National
Specialist Commissioning Team [NSCT], Stickler Diag-
nostic Service, unpublished data, June 2011).
Our current practice algorithm for managing patients with
Stickler syndrome commences with multidisciplinary team
phenotyping to direct which collagen gene is to be sequenced.
Identiﬁcation of a COL2A1 mutation conﬁrms the clinical
diagnosis of type 1 Stickler syndrome and patients are offered
genetic counseling. The risk of retinal detachment versus the
risks of retinal prophylaxis is discussed with patients and
families. Should prophylactic intervention be sought, patients
are routinely wait-listed for surgery.
Type 1 Stickler syndrome carries a life-long risk of
retinal detachment and prophylaxis is offered to patients of
any age. Historically, prophylaxis was only given after the
age of 5, when children were considered cooperative enough
to accurately phenotype the vitreous on slit-lamp bio-
microscopic examination. Currently, predictive molecular1593
Figure 3. KaplaneMeier survival curves and log-rank test outcomes for matched and unmatched prophylactic and control groups. A, Time from birth to
ﬁrst retinal detachment for the bilateral prophylaxis versus bilateral control group. B, Time from cryotherapy (or the corresponding time in the individually
matched control) to ﬁrst retinal detachment for the matched bilateral prophylaxis versus matched bilateral control group. C, Time from ﬁrst retinal
detachment to second retinal detachment for the unilateral prophylaxis versus unilateral control group. D, Time from cryotherapy (or the corresponding
time in the individually matched control) to second retinal detachment for the matched unilateral prophylaxis versus matched unilateral control group.
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conﬁrmation of the subtype of the Stickler syndrome at any
age, facilitating earlier prophylaxis. Early, accurate diag-
nosis is essential if prophylaxis is to be offered before retinal
detachment occurs. Although rare before 1.5 years of age,
the youngest child seen with bilateral retinal detachments
was 6 weeks of age; the youngest patient to receive pro-
phylaxis in our series was 10.8 months.
The rationale of the Cambridge prophylactic cryotherapy
protocol is to prevent retinal detachment secondary to giant
retinal tears; prevention of “conventional” posterior breaks
would not be expected or intended. This limitation needs to
be clariﬁed to patients consenting to treatment, explaining1594that the expectation is to substantially reduce (but not
eliminate) the risk of retinal detachment.
Cryotherapy rather than prophylactic laser retinopexy
was used for every treated patient in this series as past
experience has shown it to be safe when deployed according
to this speciﬁc protocol20 and to avoid introducing a further
confounding variable of a different treatment modality. The
results provide the ﬁrst benchmark against which future
treatment modalities or strategies could be compared.
It is accepted that the results of any form of retrospective
analysis should be interpretedwith cautionbecause theymaybe
more prone to bias; previous studies of prophylaxis in Stickler
syndrome are no exception.20,24,25 Although patients and
Table 2. Unadjusted and Sex-adjusted Hazard Ratios with 95%
Conﬁdence Intervals for Matched and Unmatched Prophylactic
and Control Groups
Group
Hazard
Ratio* 95% CI
Bilateral control vs bilateral prophylaxis
(unadjusted)
7.27* 4.47e11.87
Bilateral control vs bilateral prophylaxis
(sex adjusted)
7.40* 4.53e12.08
Matched bilateral control vs matched bilateral
prophylaxis (unadjusted)
4.77* 2.71e8.40
Matched bilateral control vs matched bilateral
prophylaxis (sex adjusted)
4.97* 2.82e8.78
Unilateral control vs unilateral prophylaxis
(unadjusted)
10.06* 4.86e20.84
Unilateral control vs unilateral prophylaxis
(sex adjusted)
10.29* 4.96e21.36
Matched unilateral control vs matched unilateral
prophylaxis (unadjusted)
6.85* 2.80e16.75
Matched unilateral control vs matched unilateral
prophylaxis (sex adjusted)
8.36* 3.24e21.57
CI ¼ conﬁdence interval.
*P<0.001.
Fincham et al  Retinal Detachment Prophylaxis in Stickler Syndromeanesthetic records were reviewed on the ﬁrst postoperative day
and 1 month after prophylaxis to evaluate individual responses
to treatment and enquire about side effects, it is accepted that
because of the retrospective nature of the current study, side
effects may be underreported. However, when thoughtfully
designed, retrospective studies, such as Lane-Claypon’s 1926
seminal investigations into breast cancer risk factors,26 can
contribute vital information that is impossible, impractical, or
unethical to ascertain prospectively.27 Given the inevitable
constraints when studying rare genetic disorders, and the
results of the current study, it is unlikely a prospective,
randomized trial could ever be commissioned to assess the
efﬁcacy of retinal prophylaxis in Stickler syndrome.
The observed treatment effect of the current retrospective
study is so large it is highly unlikely to be completely due to
biases and confounding factors. In fact, the study has been
deliberately designed to weight against the beneﬁt ofTable 3. Recorded and Reported Side Effects
Side Effect Affected, n/N (%) M
Lid/conjunctival inﬂammation
Mild 75/293 (25.6)
Moderate 40/293 (13.7)
Marked 20/293 (6.8)
Nausea and/or vomiting 35/293 (11.9)
Accommodation insufﬁciency 28/293 (9.6)
Ocular discomfort 7/293 (2.4)
Anisocoria/mydriasis 6/293 (2.0)
Photophobia 3/293 (1.0)
Itchy eyes 2/293 (0.7)
New ﬂoater 1/293 (0.3)
SD ¼ standard deviation.treatment to ensure true treatment effect is underestimated.
For example, the outcome measure of retinal detachment in
the prophylaxis groups was deﬁned to include retinopexy
without surgical repair (any postprophylactic event
requiring intervention, however minor), but only included
retinal detachment requiring formal surgical repair in the
control groups. Although there may be some uncertainty
over the precise estimate of treatment effect, outcomes show
a clear beneﬁt of prophylactic cryotherapy in reducing the
risk of retinal detachment in type 1 Stickler syndrome.
A criticism of previous studies has been appropriate
control group selection, with the suggestion that the ma-
jority of patients without retinal detachment receive pro-
phylaxis, leaving the major source of control patients as
those who have already suffered retinal detachment and
incurred the outcome event.28 This potential bias has been
addressed in the current study by creating comparable
intervention and control groups; individual patient
matching protocols ensured that patients receiving
prophylaxis did so before any potential retinal detachment
event in their individually matched control. In addition,
the prevalence of retinal detachment in the control group
for this study (53.6% [104/194]) was lower than published
prevalence estimations from Stickler syndrome support
group surveys (59.8% [189/316], where not all patients
were type 1 and many had undergone previous
cryotherapy) and large family pedigree studies (57.6%
[95/165] to 65.2% [43/66]).21e23 Our conservative esti-
mate is due to the Vitreoretinal Research Unit’s algorithm of
tracing undiagnosed family members from presenting pro-
bands and the study exclusion criteria. Furthermore,
matching protocols allowed for all retinal detachment events
(including post-prophylaxis retinopexy) and follow-up time
to be included for prophylaxis patients, but “cropped”
follow-up time resulted in lost retinal detachment events in
the control groups. These measures intentionally weight bias
against the efﬁcacy of treatment, thereby reinforcing any
demonstrated protective result. The current ﬁndings support
the previous study conducted using a sample of the current
cohort population.20
In summary, this retrospective study compares 293 pa-
tients receiving prophylaxis (and up to 36.1 years of follow-occuring after Prophylactic Cryotherapy
ean (SD) Age (yrs) Mean (SD) Time to Resolution (wks)
10.7 (9.9) <4
17.4 (18.3) <4
14.8 (16.0) <4
15.8 (12.5) <1
25.8 (14.2) 5.3 (2.5)
21.2 (18) <1
30.2 (23.1) 6.8 (2.9)
25.1 (24.6) 2.7 (1.2)
9.2 (2.5) <1
18.3 6
1595
Ophthalmology Volume 121, Number 8, August 2014up) with 194 untreated control patients. The results deﬁni-
tively demonstrate that the Cambridge prophylactic cryo-
therapy protocol is safe and signiﬁcantly reduces the risk of
retinal detachment in type 1 Stickler syndrome.
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